BioSpace News Archive

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2023, and provided pipeline and business updates.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2023 financial results and provided a business update.

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the three month period ended June 30, 2023, before markets open on Monday, August 14, 2023.

Mirum Pharmaceuticals, Inc. announced that on August 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 34,200 shares of common stock and 17,100 restricted stock units to six new employees under Mirum’s 2020 Inducement Plan.

OnPoint today announced that it will participate in the 2023 8th Annual Needham Virtual Medtech and Diagnostics Conference, which will take place on August 15th, 2023.

Defender Pharmaceuticals, Inc. (the “Company” or “Defender”) today announced that the previously reported, positive results from its Phase 3 clinical trial with DPI-386 Nasal Gel for prevention of nausea and vomiting induced by motion in adults has been selected for presentation at the upcoming 2023 Military Health System Research Symposium (MHSRS) to be held August 14 -17, 2023 in Kissimmee, FL.

Abivax SA announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares, in the United States, subject to market and other conditions, and has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission.

Ventyx Biosciences, Inc. announced financial results for the second quarter ended June 30, 2023, and highlighted recent pipeline and business progress.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported financial results and operational updates for the quarter ended June 30, 2023.

Addex Therapeutics reported its half-year and second quarter financial results for the periods ended June 30, 2023 and provided a corporate update.